InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)
InspireMD Inc. (NSPR)
NASDAQ:AMEX Investor Relations:
inspiremd.com/en/investors/investor-relations
Company Research
Source: GlobeNewswire
The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company’s C-GUARDIANS pivotal trial have now been published in the Journal of the American College of Cardiology (JACC). The data demonstrate the safety and efficacy of carotid artery stenting (CAS) with the Company’s MicroNet™ covered stent in patients with asymptomatic carotid stenosis. As shown at VIVA in late 2023 and LINC in mid-2024, C-GUARDIANS demonstrated low rates of disabling stroke or myocardial infarction (DSMI) through 30 days and low ipsilateral stroke rates through one year, with no unexpected device-related adverse events reported. This pivotal trial showed historically low ev
Show less
Read more
Impact Snapshot
Event Time:
NSPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NSPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NSPR alerts
High impacting InspireMD Inc. news events
Weekly update
A roundup of the hottest topics
NSPR
News
- InspireMD (NASDAQ:NSPR) shareholders have endured a 81% loss from investing in the stock five years ago [Yahoo! Finance]Yahoo! Finance
- Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery StentingGlobeNewswire
- InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
NSPR
Earnings
- 11/4/25 - In-Line
NSPR
Sec Filings
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- NSPR's page on the SEC website